Open AccessPhosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors
Author(s) -
Vincenzo Villani,
Krishnan K. Mahadevan,
Matteo Ligorio,
Carlos Fernándezdel Castillo,
David T. Ting,
Francesco Sabbatino,
Irene Zhang,
Mark Vangel,
Soldano Ferrone,
Andrew L. Warshaw,
Keith D. Lillemoe,
Jennifer A. Wargo,
Vikram Deshpande,
Cristina R. Ferrone
Publication year - 2016
Publication title -
annals of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.764
H-Index - 173
eISSN - 1534-4681
pISSN - 1068-9265
DOI - 10.1245/s10434-016-5171-x
Subject(s) - medicine , neuroendocrine tumors , pathology , proportional hazards model , receiver operating characteristic , oncology
The staging of pancreatic neuroendocrine tumors (PNETs) is continuously evolving. Mitotic count, as measured by hematoxylin and eosin (H&E) or Ki67 labeling index (Ki67LI), is the best predictor of disease biology. However, both of these methods have several limitations. Phosphorylated histone H3 (PHH3), a novel mitotic marker, is potentially more accurate and easier to evaluate. This study aimed to evaluate the prognostic impact of PHH3 on patients with PNETs.